Diabetic Macular Edema – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total and diagnosed prevalence of DME for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets, and 10 years for the other countries we cover.
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s DME forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of DME and the number of new diagnoses of DME?
- Of all people diagnosed with DME, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DME over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following DME subpopulations:
- Total prevalent cases.
- Total prevalent cases by disease subtypes.
- Total prevalent cases by diagnosis subtypes.
- Diagnosed prevalent cases by treatment scheme.
Note: Coverage may vary by country.
